Home / News / International / Aurobindo Pharma expecting first biosimilar approval in US in 12-18 months

Aurobindo Pharma expecting first biosimilar approval in US in 12-18 months

Aurobindo Pharma is expecting to receive an approval for its first biosimilar product in the US in the next 12-18 months, while in Europe, the company hopes a green signal by 2022.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

x

Check Also

Sirisena says opposed to forming national govt

Sirisena says opposed to forming national govt

Colombo :  Sri Lankan President Maithripala Sirisena on Monday said he is opposed ...

For the first time in 66 days, the sun will rise in the northernmost U.S. city

For the first time in 66 days, the sun will rise in the northernmost U.S. city

Wednesday is special in Utqiagvik, formerly known as Barrow, Alaska, for reasons ...